Reference health
Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, β-Funaltrexamine, and β-Chlornaltrexamine
39155-4/badge.svg){kind=icon}
35/35 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 35 checked references that resolve
resolves10.1016/S0022-3565(25)23036-1
Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
resolves10.1016/S0022-3565(24)37585-8
Stimulation of Guanosine-5′-O-(3-[35S]Thio)Triphosphate Binding by Endogenous Opioids Acting at a Cloned Mu Receptor
resolves10.1007/BF02245071
Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay
resolves10.1016/S0022-3565(25)23819-8
Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
resolves10.1016/S0022-3565(25)32103-8
Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
resolves10.1016/0006-2952(73)90196-2
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
resolves10.1016/S0022-3565(24)37088-0
Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Delta Opioid Receptor
resolves10.1016/S0022-3565(25)10898-7
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
resolves10.1111/j.1476-5381.1991.tb12239.x
Alkylation with β‐funaltrexamine suggests differences between μ‐opioid receptor systems in guinea‐pig brain and myenteric‐plexus
resolves10.1111/j.1476-5381.1985.tb11112.x
Determination of the receptor selectivity of opioid agonists in the guinea‐pig ileum and mouse vas deferens by use of β‐funaltrexamine
resolves10.1016/S0022-3565(25)38586-1
5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
resolves10.1016/S0026-895X(25)13006-X
Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
resolves10.1016/S0022-3565(25)39535-2
Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
resolves10.1016/S0022-3565(25)24539-6
Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
resolves10.1038/383819a0
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
resolves10.1016/S0022-3565(24)38137-6
Nitrocinnamoyl and Chlorocinnamoyl Derivatives of Dihydrocodeinone: In Vivo and In Vitro Characterization of μ-Selective Agonist and Antagonist Activity
resolves10.1016/S0022-3565(25)20248-8
Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
resolves10.3727/107156995819563564
14ß-CINNAMOYLAMIDOMORPHINONES AND CODEINONES. ANALOGS OF THE SELECTIVE IRREVERSIBLE ANTAGONIST CLOCINNAMOX.
resolves10.3727/107156995819563122
MOLECULAR MODELLING OF FUMARAMIDO AND CINNAMOYLAMIDO DERIVATIVES IN EPOXY-MORPHINANS. CORRELATION WITH PHARMACOLOGICAL PROFILES.
resolves10.1021/jm00177a002
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities
resolves10.1021/jm00016a010
Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 11. 3-Hydroxycyprodime and Analogs: Opioid Antagonist Profile in Comparison to Cyprodime
resolves10.1016/0014-2999(81)90355-1
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone
resolves10.1016/S0022-3565(25)39259-1
Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
resolves10.1016/S0022-3565(25)23584-4
Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
resolves10.1016/S0022-3565(24)35214-0
Ring-Constrained Orvinols as Analogs of Buprenorphine: Differences in Opioid Activity Related to Configuration of C20 Hydroxyl Group
resolves10.1016/S0026-895X(25)08634-1
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
resolves10.1016/0014-2999(82)90083-8
Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation
resolves10.1016/S0022-3565(25)32972-1
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine.
resolves10.1037/1064-1297.3.4.323
Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox.
resolves10.1016/S0022-3565(25)20932-6
Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
resolves10.1016/S0022-3565(25)38710-0
In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
resolves10.1016/S0022-3565(24)36877-6
Activation of the Cloned Human Kappa Opioid Receptor by Agonists Enhances [35S]GTPγS Binding to Membranes: Determination of Potencies and Efficacies of Ligands
resolves10.1016/S0022-5347(25)00270-8
Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
The 5 references without a DOI — listed, not checked
no DOI — not checked10.1016/S0022-3565(24)39155-4_bib12
no DOI — not checkedNew 14-aminomorphinones and codeinones.
no DOI — not checked10.1016/S0022-3565(24)39155-4_bib28
no DOI — not checkedStandard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
no DOI — not checkedCharacterization of [3H]clocinnamox binding in mouse brain membranes.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s0022-3565(24)39155-4"><img src="https://citestamp.com/citestamped/10.1016/s0022-3565(24)39155-4/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[39155-4/badge.svg)](https://citestamp.com/citestamped/10.1016/s0022-3565(24)39155-4)